On April 3, Anthropic announced its first major acquisition since the company was founded.
The target is Coefficient Bio — a New York-based biotech startup that has been operating for only eight months and has fewer than 10 employees.
The price: $400 million, paid entirely in stock.
Who is Coefficient Bio
The core team comes from Prescient Design, the computational drug discovery division of Genentech:
- Nathan Frey and Samuel Stanton, co-founders, both with backgrounds in machine learning-driven drug design
- Aris Theologis, CEO, previously held executive roles at Evozyne and Paragon Biosciences
One notable detail: Stanton was already a full-time employee of Anthropic before the acquisition was announced. This means the deal was not a negotiation with a completely unknown team from scratch, but rather a formal integration of people already collaborating internally.
Coefficient's product has almost no public information — its website offers no details and the company operates in complete stealth mode. Known capabilities include drafting drug development plans, managing clinical regulatory strategies, and discovering candidate drug molecules.
Why Anthropic made this move
In October 2025, Anthropic launched Claude for Life Sciences, customizing Claude for pharmaceutical research scenarios. At that time, the strategy was to "connect a general-purpose model to medical workflows" — providing model capabilities and letting pharmaceutical companies figure out how to use them.
At that stage, Anthropic's pharmaceutical clients included Sanofi, Novo Nordisk, and AbbVie, which were primarily using Claude for tasks such as literature reviews, data analysis, and report generation.
But real drug discovery — target identification, lead optimization, toxicity prediction — requires more than the general understanding capabilities of a language model. These tasks demand deep biochemistry knowledge and years of domain judgment. The Coefficient Bio team does exactly this.
$400 million buys not code, but professional judgment.
How hot is the entire track
For comparison, here are recent similar events:
| Event | Amount | Date |
|---|---|---|
| Anthropic acquires Coefficient Bio | $400M | April 2026 |
| Earendil Labs funding (backed by Sanofi, Pfizer) | $787M | Q1 2026 |
| OpenAI invests in 6-month-old drug AI company | $130M | Recent |
| Eli Lilly + Insilico Medicine partnership | Up to $2.75B | 2025 |
| Isomorphic Labs (Google-affiliated) funding | $600M | March 2025 |
| Eli Lilly + NVIDIA joint AI drug lab | $1B | January 2026 |
Nearly every major AI company is entering the same field through different approaches, and the time window is very concentrated.
What this acquisition signals
Anthropic has long been described as a company that prioritizes AI safety and is cautious about commercialization. Its first acquisition did not target a software tool or a code platform, but a team of life science experts.
This choice itself is a directional statement: moving from "selling model capabilities" to "building domain depth."
Connecting a general-purpose model to life sciences, and having a dedicated team working internally on life sciences, achieve results of different magnitudes. What the latter can do is difficult for the former to replicate through prompting alone.
It is currently expected that the entire Coefficient Bio team will join Anthropic's Health and Life Sciences division.
A broader question worth considering: life sciences is the first step — could law, finance, or materials science be next? If "model + vertical domain expert team" becomes Anthropic's expansion model, this $400 million acquisition is just the beginning.
Sources: Anthropic buys biotech startup Coefficient Bio in $400M deal: Reports (TechCrunch); CocoLoop, AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch (BioSpace); Anthropic Acquires Startup Coefficient Bio for About $400 Million (The Information)